Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time

PURPOSE: Denosumab, an anti–RANK ligand monoclonal antibody, significantly increases bone metastasis–free survival (BMFS; hazard ratio [HR], 0.85; P = .028) and delays time to first bone metastasis in men with nonmetastatic castration-resistant prostate cancer (CRPC) and baseline prostate-specific a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Smith, Matthew R., Saad, Fred, Oudard, Stephane, Shore, Neal, Fizazi, Karim, Sieber, Paul, Tombal, Bertrand, Damiao, Ronaldo, Marx, Gavin, Miller, Kurt, Van Veldhuizen, Peter, Morote, Juan, Ye, Zhishen, Dansey, Roger, Goessl, Carsten
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2013
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3795889/
https://ncbi.nlm.nih.gov/pubmed/24043751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.44.6716
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars